article thumbnail

Will Cava Going Public Set the Table for Other IPOs?

Successful Acquisitions

The past 18 months have marked the slowest initial public offering market since the financial crisis of 2008. There are many reasons many American companies are so hesitant to go public. Some have gotten capital from other sources like private equity, family offices, unsecured lending sources, or even friends and family.

IPO 111
article thumbnail

Cooley’s 2022 Life Sciences M&A Year in Review

Cooley M&A

Although there were 104 initial public offerings of biotechnology companies in 2021 that raised nearly $15 billion in funds, 2022 saw only 22 such IPOs collectively raising less than $2 billion. Let’s dig in.

M&A 40